Hi

We are thrilled to share some significant progress from our ongoing Phase 2B clinical trial focused on advanced-stage cancer patients experiencing symptoms of anxiety, depression and existential distress.

In this Phase 2B study, 40 participants are randomly assigned under double-blind conditions to receive Meaning-Centered Psychotherapy (MCP) alongside either the experimental treatment MB22001 (doses ranging from 4ug to 12ug) or an inactive placebo. We are proud to announce that we have reached the halfway milestone in this vital research.

MCP was developed specifically to address the feelings of despair, hopelessness, and loss of meaning that often arise in individuals facing advanced cancer. Compelling evidence supports its effectiveness in enhancing meaning and quality of life in this population.

Our hypothesis is that MB22001, when combined with MCP, will significantly alleviate symptoms of anxiety and depression compared to MCP alone. This thesis is bolstered by four years of data collection and analysis from previous clinical trials.

These encouraging results instil a high level of confidence in our management team regarding the potential of MB22001 to support cancer patients experiencing end-of-life distress.

We invite you to join us in supporting the journey toward a brighter future for mental health. Thank you for your continued interest and engagement.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true